Liminatus Pharma, Inc. Amends and Restates Merger Agreement with InnocsAI LLC
Liminatus Pharma, Inc. entered into an amended and restated merger agreement with InnocsAI LLC, detailing the terms of the definitive business combination. This development formalizes the strategic plan for Liminatus to acquire InnocsAI's AI healthcare platform.
View filing at SEC.gov →